



Ain Shams University  
Faculty of Pharmacy  
Department of Pharmaceutics and Industrial Pharmacy

# **Lipid Polymer Hybrid Nanoparticles as an Efficient Hepatic Drug Delivery System**

Thesis Submitted in Partial Fulfilment of the Requirements for the Master  
Degree in Pharmaceutical Sciences  
(**Pharmaceutical Technology**)

By

***Mohamed Hamdi Antar Amira***

Bachelor of Pharmaceutical Sciences, 2008, Al-Azhar University

**Under the supervision of**

***Prof. Gehanne Abdel Samie Awad***

Professor of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain  
Shams University

***Dr Enas Mostafa Elmowafy***

Associate Professor of Pharmaceutics and  
Industrial Pharmacy, Faculty of Pharmacy,  
Ain Shams University

***Dr Hend Mohamed Abdel-Bar***

Associate Professor of Pharmaceutics, Faculty  
of Pharmacy, University of Sadat City

***Cairo***

***2019***



جامعة عين شمس  
كلية الصيدلة  
قسم الصيدلانيات و الصيدلة الصناعية

## **جسيمات نانويه بوليمريه دهنيه هجينه كنظام توصيل دوائي فعال للكبد**

رسالة مقدمة من

**الصيدلى / محمد حمدى عنتر عميره**

مقدمة للحصول على درجة الماجستير فى العلوم الصيدلية  
(التكنولوجيا الصيدلية)

تحت إشراف

**أ.د/ جيهان عبد السميع عوض**

استاذ الصيدلانيات و الصيدله الصناعيه ، كلية الصيدلة ، جامعة عين شمس

**د/ هند محمد عبد البر**

أستاذ مساعد بقسم الصيدلانيات ،  
كلية الصيدلة ، جامعة مدينة السادات

**د/ ايناس مصطفى محمد الموائى**

أستاذ مساعد بقسم الصيدلانيات و الصيدله  
الصناعيه، كلية الصيدلة ، جامعة عين شمس

(٢٠١٩)

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

(وَكَذَلِكَ مَكَّنَّا لِيُوسُفَ فِي الْأَرْضِ  
وَلِنُعَلِّمَهُ مِمَّا تَأْوِيلِ الْأَحَادِيثِ ۚ وَاللَّهُ  
خَالِبٌ عَلَى أَمْرِهِ وَلَكِنَّ أَكْثَرَ النَّاسِ  
لَا يَعْلَمُونَ)

سورة يوسف (21)

## **Acknowledgment**

*Praise is to **ALLAH**, the most merciful and most gracious, by the help of whom this work has been completed.*

*I would first like to thank my thesis supervisor **Prof. Dr Gehanne Abdel Samie Awad**, Professor of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University. The door to **Prof. Dr Gehanne** office was always open whenever I ran into a trouble spot or had a question about my research or writing. She consistently allowed this paper to be my own work, but steered me in the right direction whenever she thought I needed it.*

*I have to record my thankfulness to **Dr Enas Elmwafy**, Associate Professor of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University for her great efforts, keen supervision, valuable guidance, caring, patience, warm advices, continuous enforcement and generous support.*

*I would like to express my sincere gratitude to my advisor **Dr Hend Mohamed Abdel-Bar**, Associate Professor of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, University of Sadat City for the continuous support of my master study and research, for her patience, motivation, enthusiasm, and immense knowledge. Her guidance helped me in all the time of research and writing of this thesis. I could not have imagined having a better advisor and mentor for this study.*

*I am also grateful to **Prof. Dr Khuloud Al-Jamal**, Professor in Drug Delivery and Nanomedicine, Institute of Pharmaceutical Science, Department of Pharmacy & Forensic Science, King's College London, UK for her kind cooperation in conducting cellular uptake, In vitro cytotoxicity and In vivo imaging and organ biodistribution investigations incorporated in this study.*


*Finally, I must express my very profound gratitude to my beloved father, my brother **Emad** and my sisters for providing me with unfailing support and continuous encouragement throughout my years of study and through the process of researching and writing this thesis. This accomplishment would not have been possible without them.*

**THANK YOU.**

**MOHAMED HAMDI EMERA**

**2019**

---



**Dedicated To  
The Soul of my  
Mother, and my  
Sister Nehal.**

---

## *List of Contents*

<i>Title</i>	<i>Page</i>
<b>List of Tables</b>	iv
<b>List of Figures</b>	vii
<b>List of Abbreviations</b>	xi
<b>Abstract</b>	xv
<b>General Introduction</b>	1
<b>Scope of Work</b>	12
<b><i>Chapter I: Preparation and Characterization of Entecavir Lipid Polymer Hybrid Nanoparticles.</i></b>	
Introduction	15
Methodology	22
Materials and Equipment	22
HPLC assay of entecavir	24
Preparation of optimized ELPH (OELPH)	25
<i>In vitro</i> characterization of the prepared OELPH	30
Statistical analysis	33
Results and Discussion	34
Analytical assay of E	34
Preparation of OELPH	39
Complete characterization of the selected OELPH	53
Effect of different lipids and lipid combinations on OELPH	56
Effect of Vitamin E coat on E GMS LPH	65
Characterization of the selected EELPH	70
Conclusions	75

<b><i>Chapter II: Preparation and Characterization of Entecavir-Hyaluronate conjugate Lipid Polymer Hybrid Nanoparticles</i></b>	
Introduction	77
Methodology	83
Materials and Equipment	83
Synthesis of E hyaluronate conjugate (E-HA)	84
Characterization of E-HA conjugate	84
Preparation and optimization of vitamin E coated E-HA LPH (EE-HA LPH)	86
<i>In vitro</i> characterization of the prepared EE-HA LPH	88
Statistical Analysis	89
Results and Discussion	90
Synthesis of E hyaluronate (E-HA) conjugate	90
Characterization of E-HA conjugate	92
Preparation of EE-HALPH	99
Physicochemical characterization of the optimized EE-HA LPH	108
Conclusions	117
<b><i>Chapter III. Biological Studies on Different Entecavir Lipid polymer Hybrid Nanoparticles</i></b>	
Introduction	119
Methodology	124
Materials and Equipment	124
Preparation of florescence labelled E LPH	126
Biological and toxicological studies of the different E LPHs	126
Statistical Analysis	129
Results and Discussion	130

<i>In vitro</i> hemolytic assay	130
<i>In vitro</i> cytotoxicity studies	131
Cellular uptake studies	132
<i>In vivo</i> biodistribution study of fluorescence labelled EE-HA LPH	137
Organ index	141
Histological examination of major organs	142
Conclusions	144
<b>Summary</b>	145
<b>References</b>	151
<b>Arabic Summary</b>	1



## List of Tables

Table No.	Title	Page
1	<i>Investigated variables in the preliminary study for the fabrication of OELPH</i>	27
2	<i>Composition of different formulae used in the preliminary study</i>	27
3	<i>Levels of CPPs, CQAs and QTPP for the preparation of OELPH using the BBD</i>	28
4	<i>The Box Behnken design matrix for the preparation of OELPH</i>	29
5	<i>Recovery of E from PBS (pH 7.4) and DMF.</i>	37
6	<i>Intra-day accuracy and precision for E in PBS pH 7.4 and DMF</i>	38
7	<i>Inter-day accuracy and precision for E in PBS pH 7.4 and DMF</i>	38
8	<i>Characterization of OELPH prepared in the preliminary study</i>	39
9	<i>Experimental design matrix of the critical process parameters and the related critical quality attributes</i>	42
10	<i>Model summary statistics for PS (Y1)</i>	43
11	<i>Model summary statistics for EE % (Y2)</i>	43
12	<i>Quantitative factor effects on the PS expressed as the coefficients of the regression equations</i>	44
13	<i>ANOVA of the obtained data from BBD for the PS of OELPH and associated p-values.</i>	45
14	<i>Quantitative factor effects on the EE% expressed as the coefficients of the regression equations</i>	49
15	<i>ANOVA of the obtained data from BBD for the EE% of OELPH and associated P-values.</i>	50
16	<i>Experimental and predicted PSs of the OELPH</i>	52
17	<i>The experimental and predicted EE % of the OELPH</i>	52
18	<i>Physicochemical characterization of the OELPH</i>	54
19	<i>In vitro release data of E from the OELPH</i>	55
20	<i>Effect of lipid modification on the PS of OELPH</i>	57

21	<i>Effect of lipid modification on EE% of OELPH</i>	59
22	<i>Composition of selected optimum lipid-modified OELPH</i>	59
23	<i>The influence of lipid modification on LE % of OELPH</i>	61
24	<i>Solubility of E in different Lipids</i>	62
25	<i>In vitro release of E from different optimum CH modified LPH</i>	63
26	<i>In vitro release of E from different optimum GMS modified LPH</i>	64
27	<i>Effect of vitamin E coating on physicochemical characteristics of GMS modified LPH.</i>	66
28	<i>In vitro release of E from different vitamin E coated GMS modified LPH</i>	69
29	<i>The effect of serum incubation on optimized EELPH PS and size distribution expressed as PDI</i>	72
30	<i>Characteristics of EELPH at various time intervals following storage at 5°C over a period of 6 months</i>	74
I	<i>Overview of some examples of the successfully prepared PDC</i>	78
II	<i>Examples for different HA-drug conjugates</i>	81
31	<i>Different CPPs with their levels, CQAs and QTPP</i>	87
32	<i>The BBD matrix of EE-HA LPH</i>	87
33	<i>Optimizing the conjugation efficiency of E to HA</i>	94
34	<i>Experimental design matrix related to the critical quality attributes of EE-HA LPH</i>	100
35	<i>Model summary statistics for PS (Y1)</i>	100
36	<i>Model summary statistics for drug association (Y2)</i>	101
37	<i>ANOVA of the obtained data from BBD for the PS of EE-HA LPH and associated p-values</i>	101
38	<i>Quantitative factor effects, expressed as the coefficients of the regression equations for the PS</i>	102
39	<i>Quantitative factor effects, expressed as the coefficients of the regression equations for the association efficiency</i>	105
40	<i>ANOVA of the obtained data from BBD for the drug association of E-HA LPH and associated p-values</i>	105
41	<i>The experimental and predicted PS and drug association of the optimized EE-HA LPH</i>	108

42	<i>Physicochemical characterization of optimized EE-HA LPH</i>	109
43	<i>In vitro release data of E from optimized EE-HA LPH</i>	110
44	<i>The effect of serum incubation on optimized EE-HA LPH PS, size distribution expressed as PDI and <math>\xi</math>.</i>	114
45	<i>Characteristics of optimized EE-HA LPH at various time intervals following storage at 5°C for 6 months</i>	116
46	<i>The obtained MFI after incubating J774 macrophage cells with different DiI-labelled E LPH</i>	134
47	<i>Change in mice body weight post IM of the optimized EE-HA LPH and PBS over 21 days</i>	138

## List of Figures

Figure No.	Title	Page
<i>I</i>	<i>The global distribution of HBV</i>	<i>2</i>
<i>II</i>	<i>Scheme of HBV life cycle and druggable targets</i>	<i>3</i>
<i>III</i>	<i>Chemical structure of E</i>	<i>4</i>
<i>IV</i>	<i>Intracellular uptake and metabolism of NAs</i>	<i>5</i>
<i>V</i>	<i>General representation of LPH</i>	<i>15</i>
<i>VI</i>	<i>Schematic representation of LPH preparation by two-step method</i>	<i>16</i>
<i>VII</i>	<i>Schematic representation of LPH preparation by one-step emulsification–solvent evaporation method. (A) Single emulsification–solvent evaporation and (B) double emulsification–solvent evaporation</i>	<i>18</i>
<i>VIII</i>	<i>Schematic representation of LPH preparation by one-step nanoprecipitation method</i>	<i>19</i>
<i>1</i>	<i>Schematic representation of OELPH preparation</i>	<i>26</i>
<i>2</i>	<i>Representative chromatogram of E (0.5µg/ml) in PBS (pH 7.4)</i>	<i>35</i>
<i>3</i>	<i>Representative chromatogram of E (0.5µg/ml) in DMF</i>	<i>35</i>
<i>4</i>	<i>Calibration curve of E in PBS pH7.4</i>	<i>35</i>
<i>5</i>	<i>Calibration curve of E in DMF</i>	<i>36</i>
<i>6</i>	<i>Effect of tween 80 concentration on PS and EE % of OELPH</i>	<i>40</i>
<i>7</i>	<i>Effect of stirring time on OELPH PS and EE %</i>	<i>41</i>
<i>8</i>	<i>Plots of the main effect of different significant critical process parameters on PS (Y1)</i>	<i>45</i>
<i>9</i>	<i>Response 3D plot for the interaction of (AC) between PLGA amount and E amount on PS (Y1)</i>	<i>47</i>
<i>10</i>	<i>Response 3D plot for the interaction of (BC) between LEC amount and E amount on PS (Y1)</i>	<i>47</i>
<i>11</i>	<i>Plots of the main effect of different significant critical process parameters on EE % (Y2)</i>	<i>50</i>
<i>12</i>	<i>Response 3D plot for the interaction of (AB) between PLGA amount and LEC amount on EE % (Y2)</i>	<i>51</i>
<i>13</i>	<i>Overlay plots depicting the design space region for the OELPH</i>	<i>52</i>
<i>14</i>	<i>PS Distribution of F1-LEC (A). F2-LEC (B) and F3-LEC (C)</i>	<i>53</i>

15	<i>In vitro release profile of E from the OELPH in PBS (pH 7.4) in the presence of FRS (50% v/v) at 37°C</i>	56
16	<i>The effect of different lipid composition modifications on PS of OELPH</i>	58
17	<i>The influence of lipid modification on <math>\xi</math> of OELPH</i>	60
18	<i>In vitro release of E from different optimum CH modified LPH</i>	64
19	<i>In vitro release of E from different GMS modified LPH</i>	65
20	<i>Effect of vitamin E coating on the PS of OELPH compared to unmodified and GMS modified ones</i>	67
21	<i>Effect of vitamin E coating on LPH <math>\xi</math> compared to unmodified and GMS modified ones</i>	67
22	<i>Effect of vitamin E coating on LPH LE% compared to unmodified and GMS modified ones</i>	68
23	<i>In vitro release of E from vitamin E coated GMS modified LPH</i>	69
24	<i>Transmission electron micrograph of the optimized EELPH</i>	71
25	<i>Atomic force micrograph of EELPH. (A) Planner view and (B) 3-D view</i>	71
26	<i>The effect of serum incubation on EELPH PS, PDI and <math>\xi</math> size, PDI and <math>\xi</math> potential</i>	73
IX	<i>Chemical structure of hyaluronic acid</i>	79
X	<i>Highlights of key features of HA derivatives as drug carrier</i>	80
XI	<i>Schematic representation of coupling reaction between E and HA</i>	82
27	<i>Schematic representation of the conjugation of E with HA</i>	91
28	<i>UV Spectrum of E, HA and E-HA conjugate (15 <math>\mu</math>g/mL) in PBS pH 7.4</i>	92
29	<i>Calibration Curve of E in PBS pH 7.4 at 254 nm</i>	93
30	<i><math>^1\text{H}</math> NMR spectra of E (A), HA (B) and E-HA conjugate (C)</i>	95
31	<i><math>^{13}\text{C}</math> NMR spectra of E (A), HA (B) and E-HA conjugate (C)</i>	97
32	<i>Mass spectra of (A) E, (B) HA and (C) E-HA conjugate</i>	98
33	<i>Line plots of the main effect of different significant CPPS on PS (Y1)</i>	102
34	<i>Response 3D plot for the interaction of (AB) between E-HA amount and LEC-GMS on PS (Y1)</i>	103

35	<i>Response 3D plot for the interaction of (AC) between E-HA amount and stirring speed on PS (Y1)</i>	103
36	<i>Response 3D plot for the interaction of (BC) between LEC-GMS amount (B) and stirring speed (C) on PS (Y1)</i>	103
37	<i>Line plots of the main effect of different significant critical process parameters on drug association (Y2)</i>	106
38	<i>Response 3D plot for the interaction of (AB) between E-HA amount and LEC-GMS amount (B) on drug association (Y2)</i>	106
39	<i>Response 3D plot for the interaction of (AC) between E-HA amount and stirring speed on drug association (Y2)</i>	106
40	<i>Overlay plots depicting the design space region for the optimized EE-HALPH</i>	107
41	<i>PS Distribution of optimized EE-HA LPH</i>	108
42	<i>In vitro release profile of E from optimized EE-HA LPH and EELPH in PBS (pH 7.4) in the presence of FBS (50% v/v) at 37°C</i>	111
43	<i>Transmission electron micrograph of optimized EE-HA LPH</i>	112
44	<i>Atomic force micrograph of optimized EE-HA LPH. (A) Planner view and (B) 3-D view</i>	112
45	<i>The effect of serum incubation on optimized EE-HA LPH PS, PDI and <math>\zeta</math></i>	115
XII	<i>Pictorial representation of a liver lobule</i>	119
XIII	<i>The role of Kupffer cells in anti-viral immunity and tissue damage during HBV infection</i>	122
XIV	<i>Role of kupffer cells in immune regulation and viral persistence during HBV infection</i>	123
46	<i>The in vitro hemolysis assay of the optimized EELPH and EE-HA LPH</i>	131
47	<i>Cell viability assay of the optimized ELPH and EELPH (A) and E-HA LPH and EE-HA LPH (B) after incubation for 48h</i>	132
48	<i>In vitro intracellular uptake of the optimized EELPH and EE-HA LPH in J774 macrophage cells by confocal laser scanning microscopy</i>	133
49	<i>Intracellular uptake of the optimized ELPH and EELPH in J774 macrophage cells by flow cytometry</i>	135
50	<i>Intracellular uptake of the optimized E-HA LPH and EE-HA LPH in J774 macrophage cells by flow cytometry</i>	136

---

51	<i>Change in mice body weight post IM injection of the optimized EE-HA LPH and PBS</i>	138
52	<i>In vivo whole body IVIS imaging and biodistribution of the optimized DiR-labelled EE-HA LPH in BALB/c mice after IM injection</i>	140
53	<i>Organ index (%) post IM injection of the optimized EE-HA LPH and PBS</i>	141
54	<i>Histological examination of major organs after biodistribution study</i>	143